Skip to content

Efficacy of Continous Regional Anesthesia Using m. Erector Spinae Catheter After VATS Procedures

Efficacy of Continous Regional Anesthesia Using m. Erector Spinae Catheter After Video-assisted Thoracic Surgery Procedures

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04062045
Enrollment
50
Registered
2019-08-20
Start date
2019-10-14
Completion date
2022-05-31
Last updated
2020-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasm of Lung, Thoracic Surgery, Video-Assisted

Keywords

Anesthesia, Conduction

Brief summary

Investigators will analyze the efficacy of continuous regional anesthesia through a catheter under erector spinae muscle in a prospective, randomized, double blind, placebo-controlled study. Investigators will include 50 adults, predicted for elective lung surgery with video-assisted thoracic surgery (VATS) technique. Patients will be randomly assigned to group A or B. Investigators will insert a catheter under the erector spinae muscle (ESC) at the T4 level of the operated side under ultrasound guidance. All patients will receive an initial bolus of 20ml levobupivacaine 0,5% through the catheter. Group A will receive a continuous infusion 5ml/h of ropivacaine 0,2% and intermittent boluses of the same local anesthetic 15ml/4h through the ESC. Group B will receive a continuous infusion of 0,9% saline in the same doses. All patients will have a PCA pump with piritramide 1mg/ml to cover the pain. All patients will receive regular doses of paracetamol and metamizole as part of multimodal analgesia. Investigators will compare pain, assessed with the VAS scale in resting and coughing and piritramide usage in both groups. Investigators will compare the incentive spirometry results at 24 and 48 hours postoperatively and observe for possible late complications.

Interventions

DRUGRopivacaine Hcl 0.2% Inj Vil 10Ml

Group A will receive the medicine through the erector spinae catheter.

DRUGSaline 0.9%

Group B will receive Saline 0,9% through the erector spinae catheter.

Sponsors

Surgery Bitenc
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Masking description

Masking the infusion mixture by using the same shape of the drug/placebo bottle and wrapping it into non-transparent sheath.

Intervention model description

Prospective, randomized, double blind, placebo controlled

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Signed written informed consent * ASA I-III * Elective video-assisted thoracic surgery with 3 ports technique * No contraindications for regional anesthesia

Exclusion criteria

* Allergy to local anesthetic * Pregnancy, breastfeeding * BMI\>35 * Inflammation in the area of ES catheter insertion * Inability to use the PCA pump

Design outcomes

Primary

MeasureTime frameDescription
Usage of opioid analgeticsContinually 48 hours post surgeryInvestigators will measure the total consumption of i.v. piritramide after surgery.

Secondary

MeasureTime frameDescription
Subjective pain scoreEvery hour in the 48 hours post surgeryInvestigators will measure subjective perception of pain with the visual analogue scale (VAS) scoring system at resting and coughing. The VAS scoring system is a numerical scale from 0-10, with 0 being no pain and 10 the strongest pain imaginable. Patients will assess their pain with the help of analogue scale with colours and faces by each number representing different VAS pain levels.
Incentive spirometry24 and 48 hours after surgeryInvestigators will assess spirometry with a manual device.
Satisfaction with analgesia1 day (at dismissal from hospital.)Investigators will assess satisfaction with qualitative and quantitative questionnaries.

Other

MeasureTime frameDescription
Complications2 monthsInvestigators will follow up the patients in weeks after surgery for possible complications.

Countries

Slovenia

Contacts

Primary ContactPolona Gams, MD
polona.gams@gmail.com00386 41 522 968
Backup ContactMaja Šoštarič, MD, as. prof
maja.sos@siol.net

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026